XORTX Therapeutics Inc.
No enriched coverage for $XRTX in the last 7 days.
No SEC Form 4 filings for $XRTX in the last 30 days.
XORTX Therapeutics has priced a public offering of 2,659,574 common shares or pre-funded warrants at US$1.88 per share, aiming to raise US$5 million in gross proceeds. The offering is expected to close around May 15, 2026, subject to regulatory approvals. Following this announcement, XRTX's stock experienced a significant negative market reaction, declining by 23.20%.
XORTX Therapeutics Inc. filed an EFFECT Form with the SEC, which became effective on May 13, 2026. This filing, with accession number 0001104659-26-057834, is a POS AM submission indicating a post-effective amendment. The company, trading under NASDAQ: XRTX, has a market cap of $3.76 million and is involved in biotechnology.
XORTX Therapeutics (XRTX) significantly reduced its net loss to US$2.66 million in 2025 due to progress in late-stage clinical programs for gout and kidney diseases, with a New Drug Application (NDA) filing targeted within 12 months. Despite this financial improvement, the company's cash reserves dwindled, emphasizing the need for critical ongoing funding to manage regulatory and market risks. This information is derived from an AI-generated summary of their SEC 20-F Annual Report.
